CME GROUP INC.(CME)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #157 of 2,879 stocksTOP 10%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CME Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CME GROUP INC. (CME), a Financials sector company. 13F Pro's AI-powered ranking engine scores CME at 74.5/100 on a 32-signal composite quality model, placing it at rank #157 of 2,879 stocks — the top 10% of the AI-ranked universe. CME scores in the top quartile across profitability (95.6), free cash flow (94.8), revenue scale (82.4). Shareholder dilution risk is elevated at 47.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CME GROUP INC. reports quarterly revenue of $1.9B, net income of $1.2B, an operating margin of 69.7%. Top institutional holders of CME by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. CME trades on the Nasdaq exchange and files with the SEC under CIK 1156375. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CME daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CME GROUP INC. directly from SEC EDGAR. CME GROUP INC.'s 13F Pro composite quality score has ranged between 8 and 78 since 2021, currently 74.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving CME's Business? Latest 10-Q Breakdown
✓ 25/25 datapoints verifiedAI-extracted from CME GROUP INC.'s 10-Q filed 2026-04-24 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
CME Group Q1 revenue surged 14% to $1.88B on 22% volume growth and strong collateral reinvestment earnings, with net income up 21% YoY to $1.15B.
Biggest Revenue Drivers
Total revenue: $1,880.1M+14% YoY
Total contract volume increased 22% to 2,210.1 million round turns, driven by market volatility from geopolitical conflict and Fed rate uncertainty.
Higher usage of certain products, increased demand by new customer segments, and price increases for certain products.
Access and communication fees, collateral management fees, equity membership subscription fees, and strategic relationship fees.
Largest Expense Items
Salary increases effective Q1 2026 and increased headcount primarily in international locations.
Higher third-party services to support ongoing Google Cloud transformation project.
Record volumes for certain equity products and addition of multiple new products launched after Q1 2025.
Amortization of acquired intangible assets.
Margins: Operating margin expanded to 69.7% from 67.5% YoY despite 7% expense growth, as revenue growth of 14% outpaced cost increases. Investment income surged 56% to $1.39B from higher collateral reinvestment earnings ($1.37B vs. $874M), partially offset by higher distributions to clearing firms ($1.25B vs. $805M).
Watch Items from the Filing
- One clearing firm represented at least 10% of clearing and transaction fees in Q1 2026; however, company notes customer trades would likely transfer to another clearing firm if firm withdraws.
- Two largest market data resellers represented approximately 26% of market data and information services revenue in Q1 2026, though company notes majority of customers would likely subscribe through alternate resellers.
- Average rate per contract declined 5% YoY to $0.652, largely due to increased micro contract volume in equities, energy and metals with lower per-contract rates.
- CME maintains $2.3B multi-currency revolving senior credit facility maturing April 2030 with approximately $2.3B excess borrowing capacity; $400M contingent letters of credit to Singapore Exchange; and $7.0B secured clearing house liquidity facility.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$1.9B
Net Income
Q1 2026
$1.2B
Free Cash Flow
Q1 2026
$1.2B
Operating Margin
Q1 2026
69.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+6.4% YoYNet Income
+15.5% YoYOperating Income
+7.6% YoYEPS (Diluted)
+15.4% YoYTotal Assets
+44.4% YoYTotal Debt
-100.0% YoYOp. Cash Flow
+15.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $6.52B +6.4% | $6.13B +9.9% | $5.58B +11.1% | $5.02B +7.0% | $4.69B -3.7% | $4.87B |
| Net Income | $4.07B +15.5% | $3.53B +9.3% | $3.23B +19.9% | $2.69B +2.0% | $2.64B +24.6% | $2.12B |
| Operating Income | $4.23B +7.6% | $3.93B +14.4% | $3.44B +13.9% | $3.02B +14.0% | $2.65B +2.2% | $2.59B |
| EPS (Diluted) | $11.16 +15.4% | $9.67 +9.1% | $8.86 +19.7% | $7.40 +1.5% | $7.29 +23.4% | $5.91 |
| Total Assets | $198.42B +44.4% | $137.45B +6.0% | $129.71B -25.5% | $174.18B -11.5% | $196.78B +161.6% | $75.22B |
| Total Debt | $0.00 -100.0% | $749.8M | $0.00 -100.0% | $16.0M -97.9% | $749.4M | $0.00 |
| Operating Cash Flow | $4.28B +15.9% | $3.69B +6.9% | $3.45B +13.0% | $3.06B +27.2% | $2.40B -10.1% | $2.67B |
AI Insight: CME Financial Trends
CME Group eliminated all debt by Q1 2025 while revenue surged 15% year-over-year to $1,880M in Q1 2026.
• Revenue jumped from $1,642M in Q1 2025 to $1,880M in Q1 2026, a 15% year-over-year increase.
• Operating income expanded from $1,108M in Q1 2025 to $1,310M in Q1 2026, up 18% year-over-year.
• Total debt eliminated completely from $750M in Q4 2024 to $0M starting Q1 2025.
• Operating cash flow increased from $1,117M in Q1 2025 to $1,260M in Q1 2026.
⚠ Equity declined from $28,728M in Q4 2025 to $26,618M in Q1 2026, a 7% drop.
⚠ Revenue volatility evident with Q3 2025 dipping to $1,538M before Q1 2026 surge to $1,880M.
AI Insight: CME Ratio Trends
CME's operating margin surged to 69.7% in Q1 2026, the highest level in the dataset, while ROIC jumped to 19.7%.
• Operating margin expanded from 61.8% in Q4 2025 to 69.7% in Q1 2026, reaching a multi-quarter high.
• ROIC strengthened from 14.2% in Q4 2025 to 19.7% in Q1 2026, the strongest showing since data began.
• Debt-to-equity ratio remained effectively zero through 2025, indicating minimal leverage.
⚠ Operating margins showed volatility, ranging from 61.8% to 69.7% over the past five quarters.
⚠ ROIC fluctuated between 13.8% and 19.7% since Q2 2025, suggesting inconsistent capital efficiency.
Get alerted when CME's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CME GROUP INC. including:
Top Institutional Holders of CME
BlackRock, Inc.
$9.3B31,448,257 shVANGUARD CAPITAL MANAGEMENT LLC
$6.9B23,367,282 shSTATE STREET CORP
$4.7B16,055,287 shMORGAN STANLEY
$2.8B9,406,843 shGEODE CAPITAL MANAGEMENT, LLC
$2.7B9,146,888 shVANGUARD PORTFOLIO MANAGEMENT LLC
$2.7B9,029,289 shCapital World Investors
$2.0B6,936,488 shBank of New York Mellon Corp
$1.4B4,832,596 shRAYMOND JAMES FINANCIAL INC
$1.3B4,374,832 shSanders Capital, LLC
$1.2B4,161,190 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $9.3B | 31,448,257 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.9B | 23,367,282 |
| STATE STREET CORP | $4.7B | 16,055,287 |
| MORGAN STANLEY | $2.8B | 9,406,843 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.7B | 9,146,888 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.7B | 9,029,289 |
| Capital World Investors | $2.0B | 6,936,488 |
| Bank of New York Mellon Corp | $1.4B | 4,832,596 |
| RAYMOND JAMES FINANCIAL INC | $1.3B | 4,374,832 |
| Sanders Capital, LLC | $1.2B | 4,161,190 |
More Financials Companies
View all Financials →Put CME on your watchlist
Track score changes the day CME GROUP INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CME a good stock to buy?
13F Pro's AI-powered analysis of CME GROUP INC. (CME) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CME are available on the CME stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CME?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CME. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CME GROUP INC.'s investment landscape.